Navigation Links
Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
Date:1/3/2008

CRANBURY, N.J., Jan. 2 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the 26th Annual JPMorgan Healthcare Conference in San Francisco, CA on Monday, January 7, 2008 at 11:30 am (Pacific Standard Time) at the Westin St. Francis Hotel.

The presentation will be webcast live and may be accessed by visiting Amicus' website at http://www.amicustherapeutics.com. A replay of the webcast will also be available on the Company's website until January 22, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company has completed Phase 1 clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)...ww.christmasseals.org to learn more, make a donat...SHINGTON, Nov. 17 Milli...month, courtesy of the American Lung Association. ...ual fundraising tradition dating back to 1907 when...culosis. , , "Most Americans alive today ...
(Date:11/18/2008)...E, Va., Nov. 18 Forty-t...ed at a November national forum to consider cuttin...c health and national economy from outbreaks of da...ed today. , , Among those innovations: , ...merican kitchen table that detects highly contagio...
(Date:11/18/2008)...ed study will enroll newly diagnosed, elderly AML ...wswire/ -- Celator Pharmaceuticals today announced...omized Phase 2 clinical study of CPX-351 (Cytarabi...th newly diagnosed acute myeloid leukemia (AML). ,...eldman, MD at the Weill Medical College of Cornel...
(Date:11/13/2008)...Study Suggests Nutritional Supplements Prior to Su...re-USNewswire/ -- Identifying,malnutrition before ...dy,contouring will significantly decrease surgical...scar quality and boost patient energy levels,acco...and Reconstructive,Surgery(R), the official medica...
Breaking Medicine Technology:American Lung Association Celebrates 101st Annual Christmas Seals Campaign 242 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference 314 1Nitec Pharma AG Announces Appointments of CEO 26 CFO in Preparation for Launch of Lodotra 28R 29 311 1Nitec Pharma AG Announces Appointments of CEO 26 CFO in Preparation for Launch of Lodotra 28R 29 311 2Nitec Pharma AG Announces Appointments of CEO 26 CFO in Preparation for Launch of Lodotra 28R 29 311 3Society for General Microbiology 161st Meeting University of Edinburgh 217 1Society for General Microbiology 161st Meeting University of Edinburgh 217 2A drug sensitive traffic cop tells potassium channels to get lost 364 1A drug sensitive traffic cop tells potassium channels to get lost 364 2
..., Germany, May 31, 2007- Results from various,clin...n patients,with advanced hepatocellular carcinoma,...tablets will be presented at the Annual,Meeting of...in,Chicago, USA from June 1 - 5, 2007. , On this o...ts,will be held on June 4, 2007. Starting at aroun...
...f Abstracts Reflects Continued Growth of Eisai,s,C...1, 2007 /PRNewswire/ -- Eisai,announced today that...eir oncology pipeline compounds have been accepted...cal Oncology (ASCO),annual meeting. ASCO takes pla...ts reveal a growing and diverse oncology clinical,...
Other Medicine Technology:Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 2Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 3Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 4
(Date:11/21/2008)... Nov. 21 Heska Corporati...ent at the New York Society of,Security Analysts,...ce on,December 2, 2008 at 1177 Avenue of the Amer... is scheduled to begin at 9:35 a.m. Eastern Time (...a live webcast and for two weeks,following the pr...
(Date:11/21/2008)...remain cautious about future antibiotic resistance...21 (HealthDay News) -- People with moderate to sev...ay be able to reduce the frequency of exacerbation...ic, a new report says. , The study, published ...ournal of Respiratory and Critical Care Medicine ,...
(Date:11/21/2008)... The University of Tex...ing of a collaborative effort to eradicate breast ...t Cancer Awareness and Research of the Americas to... the United States, and Vivian Fernandez de Torrij.... D. Anderson in the initiative are the U.S. Depar...
(Date:11/21/2008)...rs Intend To Vigorously Protect Investment And Res... 21 Dr. Stephen Joffe, ...ent to their Schedule 13D with the U.S. Securities...led a 13D disclosing ownership of 11.4% of LCA-Vis...ikPlus fixed-site laser vision correction centers ...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7
...y has selected Indian ministry of health and famil...or its "unrelenting stance on health promotion and... Welfare Anbumani Ramadoss will receive the award ...ce on Tobacco in Washington DC Friday, a ministry ...
...th African Indian Siamese twins are doing well and...nielle and Danika Lowton, born on June 21 at the A...ng their oral feeds. "They are gaining weight and...the Post newspaper quoted Wian Stander, head of th...
... live-saving stem cells, seven banks of umbilical ...st of the series will open in Gurgaon this// month...ks International, a US body, and R.J. Corporation ... will invest Rs.1 billion to build the seven repos...
...t was smuggled into the United States was found in...s over the past month. Michigan health// officials...to official reports there is no sign that the froz...rails intact, had been contaminated with the deadl...
Other Medicine News:Health News:First Cord Blood Bank in North India to be Opened in Gurgaon 2
...versatile means of sectioning fresh or fixed, anim...g blade principle which allows sectioning without ... the alteration of morphology, the destruction of ...nherent in freezing or embedding procedures are th...
...ovides a versatile means of sectioning fresh or fi... vibrating blade principle which allows sectioning...rtifacts, the alteration of morphology, the destru...effect inherent in freezing or embedding procedure...
...provides a versatile means of sectioning fresh or ... a vibrating blade principle which allows sectioni... artifacts, the alteration of morphology, the dest...s effect inherent in freezing or embedding procedu...
Instrument Cover for Vibratome.
Medicine Products: